A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge
about
Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthraxAnti-infective immunoadhesins from plants.Crystal Structure of the Engineered Neutralizing Antibody M18 Complexed to Domain 4 of the Anthrax Protective AntigenIn vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunityLethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapyAntitoxin Treatment of Inhalation Anthrax: A Systematic ReviewCharacterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatmentEfficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humansEfficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthraxEfficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease SeverityAnthrax vaccination strategiesMonoclonal antibody therapies against anthraxAntibodies for biodefenseAPEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineeringHigh-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc regionVaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthraxRecombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax.Characterization of a permissive epitope insertion site in adenovirus hexonDetection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassaysTargeting virulence not viability in the search for future antibacterials.Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.Antibodies against anthrax: mechanisms of action and clinical applications.A Novel Chimeric Anti-PA Neutralizing Antibody for Postexposure Prophylaxis and Treatment of Anthrax.Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerizationNorepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats.Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthraxNew insights into the pathogenesis and treatment of anthrax toxin-induced shock.Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Controlled release of an anthrax toxin-neutralizing antibody from hydrolytically degradable polyethylene glycol hydrogelsAnti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational AnthraxNovel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule
P2860
Q24682011-1E0BF599-729E-4A52-B2E8-8333100BC4ACQ26799080-F7E9E7B7-6971-4085-8BE0-CE3DC70053B7Q27654632-CB86F353-F68E-4901-B390-DBEF79FA27E3Q28383065-01552275-AD4A-4AF1-9C6E-E6752CC6F289Q28383094-60621458-252F-42E6-8F2E-773E1899C124Q28383765-7F500BA1-249E-4F80-8E1D-C2F9F2E43394Q28387882-7F1B116A-9E32-4BAB-87C2-94BD277034BEQ28388590-B586C029-F359-4680-85CD-DA189631B251Q28389738-44083B4A-0666-4A37-92BD-7E5289FCDBD8Q28390214-70A20C12-F805-4A00-8204-F7563620A894Q28392248-27DD7413-5A45-4419-93DB-EBE778FE457BQ28393072-8A836356-CC63-4954-9F3B-88BC254B3060Q28394941-B0C493CD-EEE7-419E-BE0C-1988D95FB396Q33284325-B32EDCDE-54E0-4E82-9819-BEE117197BD6Q33285349-2A62D387-202F-42E1-9C58-620410E1AAF5Q33451335-627995C6-7FB2-490D-B678-87BFE9DAEB03Q34125366-7CC0C9B1-4AA6-4728-B3C8-3F079495A255Q34194728-0CB2F769-D9F8-4BBE-A80E-FBD61441AE73Q34289924-3BE5E909-427D-4430-9FE5-208CD3BF4F60Q34334451-4CDAF3A6-019C-4430-8046-108F8BB8D5B1Q34483688-A109811E-AC88-4288-AAB2-7AE0B4116B74Q34648067-31202CEE-49C6-4FB7-AF9E-47AD71BE8B85Q34720183-5FEEEADF-8150-44F0-A148-F91A811247B9Q35023691-EF743688-82F9-4825-86A0-10C9D3D65153Q35073821-1E3439F9-39D5-4193-8F30-9C747221C5E5Q35610439-8007DF46-D170-4C64-97AF-5CA49DC06855Q35808793-29A1455B-626E-4BA5-9FE6-6ED888F29FC2Q36007463-A5B13A7C-03EF-4313-9F04-6EF26E7DFBD1Q36108194-7AB4B4DF-D734-41DB-A5C0-B362072C7B8FQ36155940-CCE92D83-2E84-465F-982E-0439331BE708Q36842720-F92BE1FA-87C4-426E-8485-F4DF7069CD0FQ36901955-6316DD17-40B7-45DC-8AC1-FD5F983500C1Q36989900-D392F8FC-3D8E-42E0-ACDA-3216C1648568Q37065380-E167CF07-F51E-414E-9B57-F19126951A98Q37262118-89C870B5-D64D-4E58-846F-84AF65EE5E0EQ37287801-1B5FBA34-0A12-4ADD-BDBA-04A3B4BF1A97Q37333457-5654F509-0C96-4642-9DB1-63581A0E8467Q37451219-B401CDF8-2154-42A0-81FC-FEB725A32352Q37524313-2231A1D5-D98E-4D1A-B9F4-0DAB487A7378Q37594165-9C6E967A-41FA-4086-8AA4-39AD7D345EE0
P2860
A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@ast
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@en
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@nl
type
label
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@ast
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@en
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@nl
prefLabel
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@ast
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@en
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@nl
P2093
P2860
P921
P3181
P1476
A high-affinity monoclonal ant ...... llus anthracis spore challenge
@en
P2093
George Spitalny
Giovanni D'Alia
Leslie Casey
Linda Nardone
Michael Babin
Michelle Clagett
Nehal Mohamed
Steven Jones
Steven Pincus
P2860
P304
P3181
P356
10.1128/IAI.73.2.795-802.2005
P407
P577
2005-02-01T00:00:00Z